<DOC>
	<DOCNO>NCT00475514</DOCNO>
	<brief_summary>Although predictability MRM headache attack lend preventative treatment , currently drug specifically indicate prevention MM . Such preventative therapy might administer either short term ( time around period otherwise know peri-menstrual period PMP ) continuously throughout menstrual cycle . Frovatriptan develop management migraine already license use acute treatment condition . Previous well control clinical trial highlight potential frovatriptan short-term preventative medication MM . This clinical trial mean explore indication frovatriptan expand population .</brief_summary>
	<brief_title>A Controlled Trial Investigate Efficacy Safety Frovatriptan Prevent Menstrual Migraine</brief_title>
	<detailed_description>See</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Frovatriptan</mesh_term>
	<criteria>Premenopausal female diagnose suffer MRM age 15 year , fit criterion 'difficult treat '</criteria>
	<gender>Female</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Menstrually-related Migraine Headache</keyword>
	<keyword>'Difficult Treat ' specify protocol</keyword>
</DOC>